slide1
Download
Skip this Video
Download Presentation
Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah

Loading in 2 Seconds...

play fullscreen
1 / 19

Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah - PowerPoint PPT Presentation


  • 112 Views
  • Uploaded on

AVAGAST: a randomized, double-blind placebo-controlled, phase III study of first-line capecitabine and cisplatin + bevacizumab or placebo in patients with advanced gastric cancer (AGC). Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah' - edie


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
AVAGAST: a randomized, double-blind placebo-controlled, phase III study of first-line capecitabine and cisplatin + bevacizumab or placebo in patients with advanced gastric cancer (AGC)

Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MAShah

on behalf of AVAGAST investigators

rationale for bevacizumab in agc
Rationale for Bevacizumab in AGC
  • Angiogenesis important for tumor growth, progression and metastases
  • Vascular endothelial growth factor (VEGF):
    • Critical growth factor for tumor angiogenesis
    • Over-expressed and prognostic for many human tumors
  • Bevacizumab:
    • Humanized monoclonal antibody to VEGF
    • Effective and safe in mCRC and other tumor types
    • Promising results in Phase II studies in AGC1

1Shah et al. J Clin Oncol 2006;23:2574–2576

avagast a randomized double blind placebo controlled phase iii study
AVAGAST: A Randomized Double-Blind Placebo- Controlled Phase III Study

Capecitabine*/Cisplatin (XP)

+ Placebo q3w

Locally advanced

or metastatic gastric cancer

R

Capecitabine*/Cisplatin (XP)

+ Bevacizumab q3w

Stratification factors:

1. Geographic region

2. Fluoropirimidine backbone

3. Disease status

*5-FU also allowed if cape contraindicated

Cape 1000mg/m2oral bid, d1–14, 1-week rest

Cisplatin 80mg/m2 d1

Bevacizumab 7.5 mg/kg d1

Maximum of 6 cycles of cisplatin

Cape and bevacizumab/placebo until PD

Starting dose of bev/placebo: 30 minutes, subsequent doses: 15 minutes

endpoints and statistical assumptions
Endpoints and Statistical Assumptions
  • Primary: overall survival
  • Secondary: PFS, TTP, ORR, duration of response, safety, QoL, biomarkers
  • Statistical assumptions
    • Median overall survival improvement from 10.0 to 12.8 months (HR 0.78)
    • Two-sided α-level = 0.05, 80% power
    • Required sample size: 760 patients for 517 deaths (with interim analysis)
main eligibility criteria
Main Eligibility Criteria
  • Metastatic or inoperable, locally advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ)
  • Measurable or evaluable disease
  • ECOG performance status 0–2
  • No previous chemotherapy for metastatic/locally advanced gastric cancer
  • If adjuvant chemotherapy, completed at least 6 months prior to randomization
  • No previous platinum or antiangiogenic therapy
  • No history of other malignancies
trial conduct
Trial Conduct
  • From September 2007 to December 2008, 774 patients were enrolled
  • A total of 93 centers in 17 countries were involved
  • Interim analysis
    • Planned at 345 events, but not performed according to protocol as analysis date too close to anticipated final analysis
  • Data cutoff for final analysis
    • November 2009
    • After 509 events
patient characteristics i
Patient Characteristics (I)

*1 additional patient had an ECOG PS of 4

overall survival
Overall Survival

Survival rate

XP + Placebo

XP + Bev

1.0

HR = 0.87

95% CI 0.73–1.03

p = 0.1002

0.9

0.8

0.7

12.1

0.6

0.5

10.1

0.4

0.3

0.2

0.1

0.0

12

0

15

18

21

24

3

9

6

Study month

Number at risk

54

50

0

0

XP + Placebo

XP + Bev

387

387

343

355

271

291

204

232

146

178

98

104

15

19

progression free survival
Progression-Free Survival

Progression-free survival rate

XP + Placebo

XP + Bev

1.0

HR = 0.80

95% CI 0.68–0.93

p = 0.0037

0.9

0.8

0.7

6.7

0.6

0.5

5.3

0.4

0.3

0.2

0.1

0.0

12

0

15

18

21

24

3

9

6

Study month

Number at risk

15

11

0

0

XP + Placebo

XP + Bev

387

387

279

306

145

201

86

123

55

71

32

38

3

3

overall survival subgroup analysis
Overall Survival: Subgroup Analysis

Category

Subgroup

All

All

Asia

Region

Europe

Pan-America

0

ECOG performance

1

Stomach

Site of primary disease

GE junction

Intestinal

Histologic type

Diffuse

Mixed

Locally advanced*

Disease status

Metastatic

Measurable

Disease measurability

Non-measurable

Yes

Prior gastrectomy

No

1

No. of metastatic sites at baseline

2

0

1

2

Hazard Ratio

* 29 patients with locally advanced disease only

patient characteristics by region
Patient Characteristics by Region

*1 additional patient had an ECOG PS of 4

aes of special interest to bevacizumab
AEs of Special Interest to Bevacizumab

Fistula/abscess in 2 patients on XP + Bev

Reversible posterior leukoencephalopathy syndrome in 2 patients on XP + Bev

avagast summary conclusions
AVAGAST Summary & Conclusions
  • Primary endpoint of OS not met
  • Secondary efficacy endpoints (PFS, best ORR) significantly improved, indicating clinical activity of bev + chemo in AGC
  • Heterogeneous efficacy results in both treatment arms across geographic regions
    • Hypothesis generating with regard to tumor burden, patient status, practice patterns, genetics?
  • No unexpected / new safety signals for bev
  • Further analysis ongoing, including preplanned biomarker analysis
acknowledgments
Acknowledgments
  • Patients and their families
  • Investigators, study coordinators and nurses at 93 centers in 17 countries
  • AVAGAST study team at Genentech, Roche & Chugai
ad